ATE344669T1 - 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel - Google Patents

4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel

Info

Publication number: ATE344669T1
Authority: AT; Austria
Prior art keywords: indan; fluoro; benzamide; medicinal product; synthase
Prior art date: 2001-02-13

Application number

AT02722066T

Other languages

English (en)

Inventor

Paulus Wohlfart

Teri Suzuki

Ramalinga M Dharanipragada

Alena Safarova

Armin Walser

Hartmut Strobel

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-13

Filing date

2002-02-12

Publication date

2006-11-15

2002-02-12 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE344669T1 publication Critical patent/ATE344669T1/de

Links

BOFMSBVSYVESTM-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2C1 BOFMSBVSYVESTM-UHFFFAOYSA-N 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
230000003511 endothelial effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT02722066T 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel ATE344669T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01102852		2001-02-13

Publications (1)

Publication Number	Publication Date
ATE344669T1 true ATE344669T1 (de)	2006-11-15

Family

ID=8176423

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02722066T ATE344669T1 (de)	2001-02-13	2002-02-12	4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel

Country Status (33)

Country	Link
US (3)	US6617359B2 (de)
EP (1)	EP1361882B1 (de)
JP (1)	JP4317689B2 (de)
KR (1)	KR101017531B1 (de)
CN (1)	CN100553631C (de)
AT (1)	ATE344669T1 (de)
AU (1)	AU2002253009B2 (de)
BG (1)	BG66065B1 (de)
BR (1)	BR0207178A (de)
CA (1)	CA2437966C (de)
CY (1)	CY1106278T1 (de)
CZ (1)	CZ20032154A3 (de)
DE (1)	DE60215919T2 (de)
DK (1)	DK1361882T3 (de)
EE (1)	EE05302B1 (de)
ES (1)	ES2274025T3 (de)
HR (1)	HRP20030646A2 (de)
HU (1)	HUP0302845A3 (de)
IL (2)	IL157208A0 (de)
MX (1)	MXPA03006841A (de)
MY (1)	MY135778A (de)
NO (1)	NO333522B1 (de)
NZ (1)	NZ527469A (de)
PE (1)	PE20020884A1 (de)
PL (1)	PL363452A1 (de)
PT (1)	PT1361882E (de)
RS (1)	RS51645B (de)
RU (1)	RU2308946C2 (de)
SI (1)	SI1361882T1 (de)
SK (1)	SK286513B6 (de)
TW (1)	TWI241190B (de)
WO (1)	WO2002064146A1 (de)
ZA (1)	ZA200305412B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY136316A (en) *	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) *	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
EP1388341A1 (de) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388342A1 (de) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
US7105513B2 (en) *	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003279996B2 (en)	2002-10-21	2009-07-09	Janssen Pharmaceutica, N.V.	Substituted tetralins and indanes and their use
US7045551B2 (en) *	2002-11-22	2006-05-16	Bristol-Myers Squibb Company	1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) *	2003-04-24	2006-11-07	Sanofi-Aventis Deutschland Gmbh	Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
ATE384039T1 (de) *	2003-07-03	2008-02-15	Lilly Co Eli	Indanderivate als muscarinrezeptoragonisten
WO2005018620A2 (en) *	2003-08-26	2005-03-03	Cell Center Cologne Gmbh	Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
EP1529525A1 (de) *	2003-11-06	2005-05-11	Aventis Pharma Deutschland GmbH	ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen
US8309608B2 (en) *	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
PL1708690T3 (pl)	2003-11-17	2017-01-31	Biomarin Pharmaceutical Inc.	Leczenie fenyloketonurii za pomocą BH4
AR048931A1 (es)	2004-04-21	2006-06-14	Janssen Pharmaceutica Nv	Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
KR20070084270A (ko) *	2004-11-17	2007-08-24	바이오마린 파머수티컬 인크.	안정한 정제 제형물
EP1814553A4 (de)	2004-11-19	2009-10-28	Childrens Hosp Medical Center	Gtpase-hemmer und deren verwendung zur regulierung von thrombozytenhyperaktivität
US20060185492A1 (en)	2005-02-18	2006-08-24	Francois Chianese	Shoulder bushing for saw blades
EP1741708A1 (de)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
EP1741709A1 (de)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
US7795101B2 (en) *	2006-04-03	2010-09-14	United Microelectronics Corp.	Method of forming a MOS transistor
EP1905764A1 (de)	2006-09-30	2008-04-02	Sanofi-Aventis	Substituierte 2-Phenylbenzimidazole und ihre Verwendung als Pharmazeutika
EP1923062A1 (de)	2006-11-16	2008-05-21	sanofi-aventis	Imidazo[2,1-b]thiazole und ihre Verwendung als Pharmazeutika
KR101349187B1 (ko) *	2006-12-05	2014-01-10	(주)아모레퍼시픽	지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1939180A1 (de)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamide und ihre Verwendung als Arzneimittel für die Stimulation der Expression der endothelialen NO-Synthase
EP1942104A1 (de)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropancarbonsäureamide und deren pharmazeutische Verwendung
EP1939181A1 (de)	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
EP1964841A1 (de)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]azine und deren pharmazeutische Verwendung
EP1964840A1 (de)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
US20160169868A9 (en) *	2007-05-24	2016-06-16	Calcimedica, Inc.	Calcium channel proteins and uses thereof
CN101888829A (zh) *	2007-10-09	2010-11-17	诺瓦提斯公司	缬沙坦的药物制剂
RU2400825C1 (ru) *	2009-06-10	2010-09-27	Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию"	СПОСОБ ОДНОВРЕМЕННОЙ РЕГИСТРАЦИИ Na+-ЗАВИСИМЫХ ПОТОКОВ Ca2+ И ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ ЦЕЛОГО ИЗОЛИРОВАННОГО СЕРДЦА В ЭКСПЕРИМЕНТЕ
WO2011115804A1 (en)	2010-03-17	2011-09-22	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
EP2588465B1 (de)	2010-06-30	2017-01-25	Ironwood Pharmaceuticals, Inc.	Sgc-stimulatoren
CN107266433A (zh)	2010-11-09	2017-10-20	铁木医药有限公司	sGC刺激剂
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
CN106117194A (zh)	2011-12-27	2016-11-16	铁木医药有限公司	可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
WO2014047111A1 (en)	2012-09-18	2014-03-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
EP2897953B8 (de)	2012-09-19	2019-06-26	Cyclerion Therapeutics, Inc.	Sgc-stimulatoren
EA033168B1 (ru)	2013-03-15	2019-09-30	Сайклерион Терапьютикс, Инк.	СТИМУЛЯТОРЫ sGC
CA2933250A1 (en)	2013-12-11	2015-06-18	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
EP3094327A1 (de)	2014-01-13	2016-11-23	Ironwood Pharmaceuticals, Inc.	Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
EP3194382B1 (de)	2014-09-17	2021-09-08	Cyclerion Therapeutics, Inc.	Pyrazolderivate als sgc-stimulatoren
US20170298055A1 (en)	2014-09-17	2017-10-19	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
EP3194386A2 (de)	2014-09-17	2017-07-26	Ironwood Pharmaceuticals, Inc.	Sgc-stimulatoren
CN109563087A (zh)	2016-07-07	2019-04-02	铁木医药有限公司	sGC刺激剂的固体形式
EA039683B1 (ru)	2016-07-07	2022-02-28	Сайклерион Терапьютикс, Инк.	ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932765A (en) *	1997-05-23	1999-08-03	Merck Patent Gesellschaft Mit	Nitromethyl ketones, process for preparing them and compositions containing them
US6180597B1 (en)	1998-03-19	2001-01-30	Brigham And Women's Hospital, Inc.	Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en)	1998-07-14	2000-01-27	The Brigham And Women's Hospital, Inc.	Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) *	1999-02-26	1999-03-25	Fujisawa Pharmaceutical Co., Ltd.	New 6-membered cyclic compounds
JP2003534377A (ja) *	2000-05-30	2003-11-18	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体作働薬
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es)	2001-02-13	2002-11-11	Aventis Pharma Gmbh	1,2,3,4-tetrahidronaftil aminas aciladas
MY136316A (en)	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en)	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US8309608B2 (en)	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/zh not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 ES ES02722066T patent/ES2274025T3/es not_active Expired - Lifetime
- 2002-02-12 PL PL02363452A patent/PL363452A1/xx not_active Application Discontinuation
- 2002-02-12 IL IL15720802A patent/IL157208A0/xx unknown
- 2002-02-12 DK DK02722066T patent/DK1361882T3/da active
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en not_active Ceased
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 CN CNB028048636A patent/CN100553631C/zh not_active Expired - Fee Related
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/ru not_active IP Right Cessation
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/sk not_active IP Right Cessation
- 2002-02-12 NZ NZ527469A patent/NZ527469A/xx not_active IP Right Cessation
- 2002-02-12 EE EEP200300368A patent/EE05302B1/xx not_active IP Right Cessation
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/hu unknown
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/pt not_active Application Discontinuation
- 2002-02-12 HR HR20030646A patent/HRP20030646A2/hr not_active Application Discontinuation
- 2002-02-12 SI SI200230443T patent/SI1361882T1/sl unknown
- 2002-02-12 PT PT02722066T patent/PT1361882E/pt unknown
- 2002-02-12 EP EP02722066A patent/EP1361882B1/de not_active Expired - Lifetime
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/ko not_active Expired - Fee Related
- 2002-02-12 AT AT02722066T patent/ATE344669T1/de active
- 2002-02-12 RS YU61703A patent/RS51645B/sr unknown
- 2002-02-12 DE DE60215919T patent/DE60215919T2/de not_active Expired - Lifetime
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/es active IP Right Grant
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/cs unknown
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/ja not_active Expired - Fee Related
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/es not_active Application Discontinuation
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/xx unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/bg unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/no not_active IP Right Cessation
2004
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/el unknown

Also Published As

Publication number	Publication date
CN100553631C (zh)	2009-10-28
EP1361882B1 (de)	2006-11-08
US20050054729A1 (en)	2005-03-10
CN1496264A (zh)	2004-05-12
RS61703A (sr)	2006-12-15
JP2004518713A (ja)	2004-06-24
BR0207178A (pt)	2004-03-30
BG107994A (bg)	2004-08-31
US20040019114A1 (en)	2004-01-29
CA2437966A1 (en)	2002-08-22
MXPA03006841A (es)	2003-11-13
JP4317689B2 (ja)	2009-08-19
RU2308946C2 (ru)	2007-10-27
TWI241190B (en)	2005-10-11
PE20020884A1 (es)	2002-11-25
ZA200305412B (en)	2004-09-02
EP1361882A1 (de)	2003-11-19
US20030022939A1 (en)	2003-01-30
NO20033546L (no)	2003-09-24
US6812253B2 (en)	2004-11-02
NO333522B1 (no)	2013-07-01
DE60215919T2 (de)	2007-05-31
RS51645B (sr)	2011-10-31
WO2002064146A1 (en)	2002-08-22
AU2002253009B2 (en)	2006-09-14
RU2003127750A (ru)	2005-03-10
US6617359B2 (en)	2003-09-09
CZ20032154A3 (cs)	2004-05-12
SI1361882T1 (sl)	2007-02-28
EE200300368A (et)	2003-10-15
SK286513B6 (sk)	2008-12-05
SK10112003A3 (sk)	2004-01-08
HK1062140A1 (en)	2004-10-21
IL157208A (en)	2009-09-22
BG66065B1 (bg)	2011-01-31
CA2437966C (en)	2011-06-14
NO20033546D0 (no)	2003-08-11
KR20030074809A (ko)	2003-09-19
DK1361882T3 (da)	2007-03-12
PL363452A1 (en)	2004-11-15
IL157208A0 (en)	2004-02-19
MY135778A (en)	2008-06-30
ES2274025T3 (es)	2007-05-16
HUP0302845A3 (en)	2005-11-28
NZ527469A (en)	2005-04-29
DE60215919D1 (de)	2006-12-21
PT1361882E (pt)	2007-01-31
HUP0302845A2 (hu)	2003-12-29
US7202278B2 (en)	2007-04-10
EE05302B1 (et)	2010-06-15
KR101017531B1 (ko)	2011-02-28
HRP20030646A2 (en)	2005-06-30
CY1106278T1 (el)	2011-10-12

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1361882

Country of ref document: EP

Publication	Publication Date	Title
ATE344669T1 (de)	2006-11-15	4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel
DE59911740D1 (de)	2005-04-14	Topisch anwendbare mittel gegen nagelpilzerkrankungen
ECSP066314A (es)	2006-07-28	Derivados piridilo y su uso como agentes terapéuticos
ATE381537T1 (de)	2008-01-15	Formanilid-derivative als beta2-adrenorezeptor- agonisten
SE0200979D0 (sv)	2002-03-28	New compounds
SE0100569D0 (sv)	2001-02-20	New compounds
MXPA04006051A (es)	2004-09-27	Bifenilmetil-tiazolidindionas, analogos y su uso como activadores de ppar-gamma.
SE0001899D0 (sv)	2000-05-22	New compounds
DE60115618D1 (de)	2006-01-12	Verwendung von kosmetische und pharmazeutische zubereitungen enthaltend 2-decarboxy-2-phosphino prostaglandinderivate
DOP2000000114A (es)	2002-07-15	Oxazolidinonas substituidas y su uso
NO20053644L (no)	2002-10-22	(2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
CY1105407T1 (el)	2010-04-28	Αλδονικα οξεα ολιγοσακχαριτων και η τοπικη τους χρηση
PT801649E (pt)	2002-12-31	Derivados de hidroxilamina uteis para aumentar a producao de proteinas moleculares adventicias e sua preparacao
MX2007000028A (es)	2007-07-20	Derivados de nicotinamida y su uso como agentes terapeuticos.
NO20065904L (no)	2007-02-20	Terapeutiske forbindelser
FR2744452B1 (fr)	1998-03-06	Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
DE60220055D1 (de)	2007-06-21	4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
ATE361739T1 (de)	2007-06-15	Haarpflegemittel enthaltend eine styrylpyrazole verbindung
DK1343472T3 (da)	2006-09-25	Thixotropisk næsespray
EA200400707A1 (ru)	2004-10-28	Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
CY1111900T1 (el)	2015-11-04	Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
UY28129A1 (es)	2004-07-30	Complejos de e.-2-metoxi.-n-(3-(4-(3-metil-4-(6-metil piridin-3- iloxi)fenilamino)quinazolin-6-il)alil)acetamida, su procedimiento de producción y uso
PE20030236A1 (es)	2003-04-10	Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
WO2004033484A3 (en)	2004-06-10	Use of stable glutamine derivatives to improve drug absorption
AR030945A1 (es)	2003-09-03	Amidas de acido fenilciclohexanocarboxilico sustituido y su uso